Levetiracetam

Wyllie's Treatment of Epilepsy: Principles and Practice: Fifth Edition

Volumn , Issue , 2012, Pages 731-735

  Sirven, Joseph I ^a   Drazkowski, Joseph ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944394150     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (41)

1. Genton P, Van Vleyman BV. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord. 2000;2:99-105.
2. Keppra. In: Physician's Desk Reference®. 62nd ed. Montvale, NJ: Medical Economics; 2008.
3. Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol. 1998;353:191-206.
4. Loscher W, Honack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol. 1993;232:147-158.
5. Gower AJ, Hirsch E, Boehrer A, et al. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 1995;22:207-213.
6. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995;286:137-146.
7. Lynch BA, Lamberg N, Nocka K, et al. The synpatic vesicle protein SVA2 is the binding site for the antiepileptic drug LEV. Proc Natl Acad Sci. 2004;101(26):9861-9866.
8. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43:9-18.
9. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002;136:659-672.
10. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca (2+) current in pyramidal neurones of rat hippocampal slices. Neurosci Lett. 2001;306:5-8.
11. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77-85.
12. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia. 2001;42:1574-1579.
13. Nicolas JM, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos. 1999;27:250-254.
14. Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 2003;53:47-56.
15. Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women. Epilepsia. 2002;43:697-702.
16. Levy RH, Ragueneau-Majlessi I, Baltes E. Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. Epilepsy Res. 2001; 46:93-99.
17. Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. Epilepsy Res. 2001;47:55-63.
18. Gidal BE, Baltes E, Otoul C, et al. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Research. 2005;64(1-2):1-11.
19. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology. 2000;55:236-242.
20. Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia. 2000;4:1179-1186.
21. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures; a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia. 2000; 41:1276-1283.
22. Abou-Khalil B, Hemdal P, Privitera M. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day (-1) in adult patients with refractory epilepsy. Seizure. 2003;12:141-149.
23. Krakow K, Walker M, Otoul C, et al. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology. 2001;56:1772-1774.
24. Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure. 2003;12:131-135.
25. Betts T, Waegemans T, Crawford P. A multicentre, double-blind, randomized parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure. 2000;9:80-87.
26. Grant R, Shorvon SD. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy. Epilepsy Res. 2000;42:89-95.
27. Ben-Menachem E, Edrich P, Van Vleyman B, et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res. 2003;53:57-64.
28. Betts T, Yarrow H, Greenhill L, et al. Clinical experience of marketed levetiracetam in an epilepsy clinic-a one year follow up study. Seizure. 2003;12:136-140.
29. Levetiracetam. Available at: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm?fuseaction=Search.Label_ApprovalHistory. Accessed January 24, 2009.
30. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402-408.
31. Perry S, Holt P, Benatar M. Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age. J Child Neurol. 2008;23:515-519.
32. Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia. 2002;43:518-524.
33. Harden C. Safety profile of levetiracetam. Epilepsia. 2001;42(suppl 4):36-39.
34. Frost MD, Gustafson MC, Ritter FJ. Use of levetiracetam in children younger than 2 years [abstract]. Epilepsia. 2002;43(suppl 7):57.
35. Peltola J, Coetzee C, Jimenez J, et al. Once daily extended release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy; a double blind, randomized, placebo-controlled trial. Epilepsia. 2009;50:406-414.
36. Baulac M, Brodie MJ, Elger CE, et al. Levetiracetam intravenous infusion as alternative to oral dosing in patients with partial-onset seizures. Epilepsia. 2007;48:589-592.
37. Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006;47:1128-1135.
38. Ramael S, De Smedt F, Toublanc N, et al. Single dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther. 2006;28:734-744.
39. Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006;66:1654-1660.
40. Ferrendelli JA, French J, Leppik I, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav. 2003;4:702-709.
41. French J, Arrigo C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia. 2005;46:324-326.